Monda Steven M, Lui Hansen T, Pratsinis Manolis A, Chandrasekar Thenappan, Evans Christopher P, Dall'Era Marc A
Department of Urologic Surgery, University of California Davis, Davis, CA, USA.
Department of Urology, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland.
Eur Urol Open Sci. 2023 May 10;52:137-144. doi: 10.1016/j.euros.2023.04.015. eCollection 2023 Jun.
Current data on the association between tumor size, subtype, and metastases, and thresholds for intervention, for renal cell carcinoma (RCC), are largely based on single-center nephrectomy registries that may under-represent those presenting with metastatic disease.
We sought to assess tumor size and histologic subtype in relation to metastatic status at presentation for patients with RCC.
Using Surveillance, Epidemiology and End Results cancer registry data, we identified patients with a diagnosis of RCC made between 2004 and 2019, and a known size of primary tumor. We used nodal and metastatic TNM staging to assess metastatic disease at presentation.
We report the proportion of metastatic disease across varying tumor sizes for clear cell (ccRCC), papillary (pRCC), and chromophobe (chRCC) RCC. We also examine sarcomatoid RCC and RCC with sarcomatoid features (sarcRCC). Logistic regression models were used to model the likelihood of metastatic disease for each histologic subtype.
Of 181 096 RCC patients included, 23 829 had metastatic disease. For any RCC, metastatic rates of 3.6%, 13.1%, 30.3%, and 45.1% were observed for tumors ≤4, 4-≤7, 7-≤10, and >10 cm, respectively. Metastatic rates of chRCC were low at even large sizes, 11.0% at >10 cm. In contrast, sarcRCC had high metastatic rates at all sizes, 27.1% at ≤4 cm. Metastatic rates for ccRCC and pRCC increased steadily above 3 cm. For any RCC and each evaluated subtype, tumor size was found to be associated with metastatic disease on logistic regression ( < 0.001).
The likelihood of a renal mass being metastatic varies greatly with both its subtype and size. We report higher likelihoods of metastatic disease across tumor sizes compared with what has been reported previously. These results may help clinicians pick appropriate thresholds for intervention and candidates for active surveillance.
We find that the metastatic probability of renal cell carcinoma varies greatly with subtype and increases with tumor size.
目前关于肾细胞癌(RCC)的肿瘤大小、亚型与转移之间的关联以及干预阈值的数据,在很大程度上基于单中心肾切除术登记处的数据,这些数据可能无法充分代表那些出现转移性疾病的患者。
我们试图评估RCC患者就诊时肿瘤大小和组织学亚型与转移状态的关系。
设计、设置和参与者:利用监测、流行病学和最终结果癌症登记数据,我们确定了2004年至2019年间诊断为RCC且已知原发肿瘤大小的患者。我们使用淋巴结和转移性TNM分期来评估就诊时的转移性疾病。
我们报告了透明细胞(ccRCC)、乳头状(pRCC)和嫌色细胞(chRCC)RCC在不同肿瘤大小下的转移疾病比例。我们还研究了肉瘤样RCC和具有肉瘤样特征的RCC(sarcRCC)。使用逻辑回归模型对每种组织学亚型的转移疾病可能性进行建模。
在纳入的181096例RCC患者中,23829例有转移性疾病。对于任何RCC,肿瘤≤4 cm、4-≤7 cm、7-≤10 cm和>10 cm时的转移率分别为3.6%、13.1%、30.3%和45.1%。即使在大尺寸时,chRCC的转移率也很低,>10 cm时为11.0%。相比之下,sarcRCC在所有尺寸下的转移率都很高,≤4 cm时为27.1%。ccRCC和pRCC的转移率在3 cm以上稳步上升。对于任何RCC和每种评估的亚型,在逻辑回归中发现肿瘤大小与转移疾病相关(<0.001)。
肾肿块转移的可能性因其亚型和大小而异。与之前报道的相比,我们报告了不同肿瘤大小下转移疾病的更高可能性。这些结果可能有助于临床医生选择合适的干预阈值和主动监测的候选者。
我们发现肾细胞癌的转移概率因亚型而异,并随肿瘤大小增加。